Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Final analyses confirmed that addition of ixazomib to lenalidomide and dexamethasone (Rd) did not result in an improvement in overall survival (median follow up 85 months, median overall survival 53.6 versus 51.6 months for placebo plus Rd; HR, 0.939; P = 0.495).

Journal of Clinical Oncology